Inari Medical Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
Inari Medical (NASDAQ:NARI) has received mixed analyst ratings over the past three months, with 4 analysts offering diverse perspectives. The average 12-month price target for NARI is $73.00, with a high estimate of $85.00 and a low of $65.00, marking a slight increase from the previous target of $71.67. Analysts from Needham, Truist Securities, and Piper Sandler have adjusted their ratings and price targets, reflecting their latest views on the company's performance. Inari Medical, a medical device company, has shown strong financial performance with a revenue growth of 31.35%, a net margin of 2.5%, and an ROE of 0.71%. The company's market capitalization is below industry averages, but it has a low debt-to-equity ratio of 0.07.
January 23, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inari Medical has received mixed reviews from analysts, with an updated average price target of $73.00. The company's strong financial performance and low debt levels may positively influence investor sentiment.
The mixed analyst ratings, with recent updates to price targets and ratings, suggest a cautiously optimistic outlook for NARI. The company's strong financial performance, particularly in revenue growth and profitability, alongside a low debt-to-equity ratio, are positive indicators that could lead to short-term price appreciation. The relevance of the news is high as it directly pertains to NARI, and the importance is significant given that analyst ratings can influence investor sentiment. The confidence level is set at 80 due to the inherent uncertainty in how the market will interpret and react to analyst ratings.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100